4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Ma'ema'e Waena >99.0% (HPLC)
ʻO Ruifu Chemical Supply Lenvatinib Mesylate Intermediates Me ka Maʻemaʻe Kiʻekiʻe
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Inoa Kimia | 4-Amino-3-Chlorophenol |
Nā huaʻōlelo like | 3-Chloro-4-Aminophenol;Lenvaint-G |
Helu CAS | 17609-80-2 |
Helu CAT | RF-PI1968 |
Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
ʻĀpana Molekala | C6H6ClNO |
Kaumaha Molecular | 143.57 |
ʻO ka mānoanoa | 1.406±0.060 g/cm3 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Pada Paʻa Palaka |
1 H NMR Spectrum | Kūlike me ka hoʻolālā |
ʻIkepili-HPLC | ʻO ka manawa paʻa e like me ka maʻamau |
Maʻemaʻe / Kaʻina Hanana | >99.0% (HPLC) |
Lae hehee | 138.0~141.0 ℃ |
Nalo ma ka maloo | <1.00% |
Koena ma ka Ignition | <0.30% |
Huina paumaele | <1.00% |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | Waena o Lenvatinib Mesylate (CAS: 857890-39-2) |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
ʻO 4-Amino-3-Chlorophenol (CAS: 17609-80-2) he mea koʻikoʻi ka lāʻau lapaʻau koʻikoʻi, i hoʻohana nui ʻia i ka hoʻolālā a me ka synthesis o nā anti-tumor, nā maʻi cardiovascular, nā maʻi maʻi neurological.ʻO 4-Amino-3-Chlorophenol kahi mea koʻikoʻi waena i ka hoʻomākaukau ʻana o Lenvatinib Mesylate (CAS: 857890-39-2).Hoʻomohala ʻia e Eisai Inc., ʻo lenvatinib mesylate he mea hoʻokae endothelial growth factor receptor (VEGF) i loaʻa ka hana e kūʻē i nā subtypes VEGF 1, 2, a me 3 a ua ʻae ʻia e ka FDA ma 2015 no ka mālama ʻana i ka maʻi maʻi thyroid like ʻole. hou, metastatic, a holomua paha a ʻaʻole i pane i ka lāʻau iodine radioactive.I Mei 2016, ua ʻae ka FDA i ka lāʻau lapaʻau ma ke ʻano he hui hui me everolimus no ka mālama ʻana i ka maʻi maʻi maʻi renal cell carcinoma.No ka mea, ua manaʻo ʻia ʻo VEGF (a me ka fibroblast growth factor receptors, i kapa ʻia ʻo FGFRs) i ke kuleana i nā ala hōʻailona cardiovascular, ua manaʻo ʻia ʻo VEGF2R a me FGFR inhibition nā mea hana ma hope o ka hopena mua o ka lenvatinib mesylate, ʻo ia ka hypertension.